

December 20, 2017

Company name: Mitsubishi Tanabe Pharma Corporation  
Representative: Masayuki Mitsuka  
President and Representative Director  
Code number: 4508, First Section, Tokyo Stock Exchange  
Contact: Yoshifumi Mifune, General Manager,  
Corporate Communications Department  
(TEL: +81-6-6205-5211)

**Update of Previous Disclosure**  
**License Agreement with Kolon Life Science on Invossa®**

Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced today that MTPC notified Kolon Life Science, Inc. (Head Office: Gwacheon, Republic of Korea; hereinafter, "KLS") that MTPC seeks to cancel the License Agreement between MTPC and KLS (announced on November 1, 2016) for Invossa®, a cell therapy product for improvement of knee osteoarthritis symptoms. MTPC has started negotiations with KLS regarding the cancellation of the License Agreement.

Additional guidance regarding the impact on the financial forecast of MTPC will be presented as soon as it is determined.

End